Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00899405
First received: May 9, 2009
Last updated: July 7, 2009
Last verified: July 2009

May 9, 2009
July 7, 2009
May 2005
December 2008   (final data collection date for primary outcome measure)
Mutational status of the EGFR pathway [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00899405 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

OBJECTIVES:

  • Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
  • Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.

OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Lung Cancer
  • Genetic: DNA analysis
  • Genetic: mutation analysis
  • Genetic: polymerase chain reaction
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
December 2008   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • May have received prior EGFR inhibitors
Both
18 Years and older
No
Not Provided
United States
 
NCT00899405
CDR0000583056, UCD-155, UCD-200412410
Not Provided
Not Provided
University of California, Davis
Not Provided
Principal Investigator: Philip C. Mack, PhD University of California, Davis
National Cancer Institute (NCI)
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP